As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.
13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 266 266 |
21%
21%
|
|
| Gross Profit | 236 236 |
23%
23%
|
|
| EBITDA | 106 106 |
2,068%
2,068%
|
|
| EBIT (Operating Income) EBIT | 87 87 |
449%
449%
|
|
| Net Profit | 78 78 |
445%
445%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
| Head office | Canada |
| CEO | Peter Greenleaf |
| Employees | 130 |
| Founded | 1993 |
| Website | www.auriniapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


